Co-Development. If Dynavax exercises its option to co-develop a GSK Product under Section 5.5, the royalty rate applicable to such GSK Product shall be increased by [ * ] above the applicable royalty rate set forth under Section 6.4.1, as adjusted pursuant to this Section 6.4.2.
Appears in 2 contracts
Sources: Research and Development Collaboration and License Agreement (Dynavax Technologies Corp), Research and Development Collaboration and License Agreement (Dynavax Technologies Corp)